Ruxotemitide

DB12748InvestigationalSmall molecule

LTX-315 has been used in trials studying the treatment of Cancer, Lymphoma, Melanoma, Carcinoma, and Breast Cancer, among others.

Mechanism: Pharmacologically active on Toll-like receptor 7 and Phospholipid-transporting ATPase IF
Curator reviewed
Formula / weight: C₇₈H₁₀₆N₁₈O₉ · 1439.823 g/mol (avg)
Code names: LTX-315

Resolves to

Compound

UNII75FBL12IZ7CAS1345407-05-7PubChem46200994

Structure

InChIKeyGGAKLYWEFZCVIT-TVEKFXMRSA-NSMILES

NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(N)=O

Targets

Q9NYK1TLR7Q9Y2G3ATP11B

What you can answer from here — as of September 10, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ruxotemitide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account